Related Experiment Video
Updated: Jan 24, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease
Philip S Watson1, Patricia L Novy2, Leonard R Friedland2
1GSK, Rockville, MD, USA.
Abstract:
Meningococcal serogroup B (MenB) has become the main cause of invasive meningococcal disease in industrialized countries in recent years. The diversity of MenB strains and poor immunogenicity of the MenB capsular polysaccharide have made vaccine development challenging. Two MenB vaccines, including factor H binding protein (fHbp) as a major antigenic component, are now licensed for use. In addition to fHbp variant 1, the multicomponent vaccine 4CMenB contains neisserial heparin binding antigen, Neisseria adhesin A, and outer membrane vesicles containing porin A. The vast majority of circulating MenB strains contain genes encoding at least one 4CMenB component and many express genes for more than one vaccine antigen. Recent studies have suggested that serum bactericidal activity is enhanced against strains that express two or more vaccine antigens. Bacterial killing may also occur when antibodies to vaccine components are collectively present at levels that would individually be sub-lethal. The evaluation of immune responses to separate vaccine components does not take cooperative activity into account and may underestimate the overall protection. Available data on 4CMenB effectiveness indicate that this multicomponent vaccine affords broad coverage and protection against MenB disease. 4CMenB also has the potential to protect against disease caused by non-MenB meningococci and Neisseria gonorrhoeae.
Insights
Meningococcal serogroup B (MenB) vaccines, like 4CMenB, offer broad protection against invasive MenB disease. This multicomponent vaccine may also protect against other meningococcal strains and gonorrhea.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Meningococcal serogroup B (MenB) is a leading cause of invasive meningococcal disease in industrialized nations.
- MenB vaccine development is challenging due to strain diversity and poor immunogenicity of the MenB capsular polysaccharide.
- Two MenB vaccines utilizing factor H binding protein (fHbp) are now available.
Purpose of the Study:
- To evaluate the effectiveness of the multicomponent 4CMenB vaccine against Meningococcal serogroup B (MenB) disease.
- To assess the potential of 4CMenB to provide cross-protection against non-MenB meningococci and Neisseria gonorrhoeae.
Main Methods:
- Analysis of circulating MenB strains for vaccine antigen gene content.
- Review of studies on serum bactericidal activity against strains expressing multiple vaccine antigens.
- Evaluation of available data on 4CMenB effectiveness.
Main Results:
- Most circulating MenB strains possess genes for at least one 4CMenB component, with many expressing multiple antigens.
- Serum bactericidal activity may be enhanced when antibodies to multiple vaccine components are present.
- 4CMenB demonstrates broad coverage and protection against MenB disease.
Conclusions:
- The multicomponent 4CMenB vaccine provides broad protection against MenB disease.
- Cooperative antibody activity against multiple vaccine components may enhance bacterial killing.
- 4CMenB shows potential for cross-protection against other meningococcal serogroups and Neisseria gonorrhoeae.
Related Concept Videos
Vaccinations
Coronary Artery Disease IV: Preventive Measures
Benefits of Self-Esteem
Cancer Prevention
Some...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Prevention of Further Absorption of Poison

